Petrovai Gheorghe, Truant Stéphanie, Langlois Carole, Bouras Ahmed F, Lemaire Stéphanie, Buob David, Leteurtre Emmanuelle, Boleslawski Emmanuel, Pruvot François-René
Department of Digestive Surgery and Transplantation, University Hospital Centre [Centre Hospitalier Universitaire (CHU)], University of Lille Nord de France, Lille, France.
HPB (Oxford). 2013 Dec;15(12):919-27. doi: 10.1111/hpb.12056. Epub 2013 Feb 26.
Following hepatic resection, liver regeneration has been associated with concurrent splenic hypertrophy. The mechanisms of this phenomenon are unknown, may be multiple and include: splanchnic sequestration caused by a reduction in the hepatic mass; hepatic growth factors that may indirectly act on the spleen, and the redistribution of the total reticuloendothelial system.
Seventy-five patients (40 males; median age: 60 years) who underwent minor (16%) or major (84%) hepatectomy between September 2004 and October 2009 were included. Prospective measurements of liver and spleen volumes were obtained preoperatively and postoperatively 1 month after hepatectomy using computed tomography (CT). The future remnant liver volume (RLV) was calculated on preoperative CT and the extent of resection was expressed as the RLV divided by total liver volume (TLV). Liver and spleen hypertrophy were expressed according to the absolute gain or relative increase in the initial volumes (%).The presence of fibrosis >F1, associated extrahepatic resection (except minor resections), and previous hepatectomy (major or minor) within 3 months represented exclusion criteria.
Mean ± standard deviation (SD) liver volume at 1 month was higher than RLV (1187 ± 286 cm(3) versus 764 ± 421 cm(3) ; P < 0.001). Mean ± SD splenic volume increased from 252 ± 100 cm(3) preoperatively to 300 ± 111 cm(3) at 1 month (P < 0.001). Liver and splenic hypertrophy were significant after major hepatectomies (+100% and +26%, respectively; P < 0.001), but not after minor hepatectomies. Liver hypertrophy was inversely correlated to RLV/TLV (r = -0.687, P < 0.001). Splenic hypertrophy was not correlated to RLV/TLV. Liver and splenic hypertrophy were linearly correlated (r = 0.495, P < 0.001). Neoadjuvant chemotherapy (n = 37), preoperative portal vein embolization (n = 10) and postoperative complications (overall: n = 25; major: n = 10; infectious: n = 6) had no impact on hepatic or splenic hypertrophy.
Splenic hypertrophy occurred after major hepatectomy, but was not correlated to the extent of resection, by contrast with liver hypertrophy. Nevertheless, there was a linear correlation between splenic and liver hypertrophy. This correlation suggests the hypothesis of a splenic action of hepatic growth factors or a redistribution of the total reticuloendothelial system rather than an effect of reduction of the portal bed or hepatic outflow.
肝切除术后,肝脏再生与同时发生的脾肿大有关。这种现象的机制尚不清楚,可能是多方面的,包括:肝脏体积减小导致的内脏隔离;可能间接作用于脾脏的肝脏生长因子,以及整个网状内皮系统的重新分布。
纳入2004年9月至2009年10月间接受小范围(16%)或大范围(84%)肝切除术的75例患者(40例男性;中位年龄:60岁)。术前及肝切除术后1个月使用计算机断层扫描(CT)对肝脏和脾脏体积进行前瞻性测量。术前CT计算未来残余肝体积(RLV),切除范围以RLV除以全肝体积(TLV)表示。肝脏和脾脏肥大根据初始体积的绝对增加或相对增加(%)来表示。纤维化> F1、相关肝外切除(小范围切除除外)以及3个月内既往肝切除术(大范围或小范围)的存在为排除标准。
1个月时肝脏平均±标准差(SD)体积高于RLV(1187±286 cm³对764±421 cm³;P < 0.001)。脾脏平均±SD体积从术前的252±100 cm³增加到1个月时的300±111 cm³(P < 0.001)。大范围肝切除术后肝脏和脾脏肥大显著(分别为+100%和+26%;P < 0.001),但小范围肝切除术后不显著。肝脏肥大与RLV/TLV呈负相关(r = -0.687,P < 0.001)。脾脏肥大与RLV/TLV无关。肝脏和脾脏肥大呈线性相关(r = 0.495,P < 0.001)。新辅助化疗(n = 37)、术前门静脉栓塞(n = 10)和术后并发症(总体:n = 25;严重:n = 10;感染性:n = 6)对肝脏或脾脏肥大无影响。
与肝脏肥大不同,大范围肝切除术后发生脾肿大,但与切除范围无关。然而,脾脏和肝脏肥大之间存在线性相关性。这种相关性提示了肝脏生长因子对脾脏有作用或整个网状内皮系统重新分布的假说,而非门静脉床减少或肝流出道的影响。